Laurephile Desrosiers, DO
Urogynecology and Reconstructive Pelvic Surgery · New Orleans, LANPI 1861652570
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,674 of the $4,057 with a category attached, or 65.9%. It is spread thinly across 18 manufacturers, the largest accounting for just 23.1%. Reporting peaked in 2020 at $1,437 and has fallen 85.3% since, to $212 in 2025.
Across 109 payments — averaging $37.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$937
- Applied Medical Resources Corporation$854
- Medtronic$503
- Teva Pharmaceuticals USA, Inc.$399
- Boston Scientific$327
- Sumitomo Pharma America, Inc.$238
- plus $800 from 12 others
What the payments were for
- Travel & lodging$1,33233%
- Food & beverage$2,67466%
- Education$311%
- Entertainment$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 11 | $937 |
| Applied Medical Resources Corporation | 3 | $854 |
| Medtronic | 15 | $503 |
| Teva Pharmaceuticals USA, Inc. | 20 | $399 |
| Boston Scientific | 10 | $327 |
| Sumitomo Pharma America, Inc. | 11 | $238 |
| Axonics, Inc. | 8 | $170 |
| Pfizer | 8 | $130 |
| AbbVie(2 entities) | 7 | $126 |
| Valencia Technologies Corporation | 2 | $118 |
| Astellas Pharma US Inc | 7 | $113 |
| Urogen Pharma, Inc. | 1 | $32 |
| Femselect Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Provepharm Inc. | 1 | $19 |
| Merck | 1 | $18 |
| Mission Pharmacal Company | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GELPOINT VPATH$840
- ALTIS$519
- INTERSTIM$104
- eCoin Device Kit$100
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 177 | $114,654 |
| MyrbetriqMirabegron | 133 | $79,391 |
| PremarinEstrogens, Conjugated | 91 | $41,352 |
| Estradiol | 106 | $6,914 |
| Solifenacin Succinate | 106 | $2,820 |
| Methenamine Hippurate | 26 | $994 |
| Oxybutynin Chloride ErOxybutynin Chloride | 49 | $781 |
| Clobetasol Propionate | 19 | $715 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $156 |
| Fluconazole | 27 | $152 |
| Cephalexin | 31 | $115 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 30 | $106 |
| Ciprofloxacin Hcl | 13 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $238 | $114,654177 claims |
| Astellas Pharma US IncMyrbetriq | $113 | $79,391133 claims |
| PfizerPremarin | $130 | $41,35291 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other urogynecology and reconstructive pelvic surgery in New Orleans
- Leise KnoeppNew Orleans$6K
- Lekha HotaNew Orleans$5K
- Lisa PeacockNew Orleans$2K
- Dani ZoorobShreveport$238K
- Ryan KrlinMetairie$39K
- Elizabeth RourkeMetairie$6K
- Barry HallnerBaton Rouge$5K
- Ralph ChessonMetairie$290
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.